January 22, 2025 03:02 PM EST
R&D
China
Cell/Gene Tx

Chi­nese start­up be­gins first tri­al of in vi­vo CRISPR ther­a­py for blood dis­ease

Ryan Cross

Senior Science Correspondent

A lit­tle-known Chi­nese biotech start­up has zipped ahead of US com­pa­nies in one of the gene edit­ing field’s most com­pet­i­tive races.
YolTech Ther­a­peu­tics

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Bio­gen makes cuts across its re­search unit, shift­ing fo­cus to ‘ex­ter­nal op­por­tu­ni­ties’

RFK Jr. says he’ll di­vest in­ter­ests in CRISPR Ther­a­peu­tics if con­firmed for HHS chief

'No mir­a­cles': What Re­gen­eron's George Yan­copou­los re­al­ly thinks of AI

GLP-1s can cut the risk of Alzheimer’s. What does that mean for No­vo Nordisk?

As­traZeneca ex­ec stress­es Calquence's patent life ahead of next Medicare ne­go­ti­a­tions

sponsored

Fu­el­ing More Break­throughs: Man­u­fac­tur­ing In­no­va­tion to Ex­pand Gene Ther­a­py’s Reach

A service from the Financial Times